Barclays Reiterates “$9.00” Price Target for Endo International (ENDP)
Several other equities analysts also recently weighed in on ENDP. BidaskClub upgraded shares of Endo International from a strong sell rating to a sell rating in a research note on Tuesday, March 6th. Canaccord Genuity set a $7.00 price objective on shares of Endo International and gave the company a hold rating in a research report on Tuesday, February 27th. Oppenheimer restated a hold rating on shares of Endo International in a research report on Tuesday, February 27th. BMO Capital Markets cut their price objective on shares of Endo International from $10.00 to $9.00 and set a market perform rating for the company in a research report on Monday, March 5th. Finally, Gabelli lowered shares of Endo International from a buy rating to a hold rating in a research report on Wednesday, February 28th. Three analysts have rated the stock with a sell rating, sixteen have issued a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the stock. Endo International has an average rating of Hold and an average price target of $10.22.
Endo International (ENDP) opened at $7.01 on Friday. The firm has a market cap of $1,570.00, a PE ratio of -1.27 and a beta of 0.35. The company has a debt-to-equity ratio of 17.00, a current ratio of 1.02 and a quick ratio of 0.85. Endo International has a 12 month low of $5.77 and a 12 month high of $14.15.
A number of institutional investors have recently made changes to their positions in the business. UBS Asset Management Americas Inc. lifted its position in Endo International by 4.4% during the fourth quarter. UBS Asset Management Americas Inc. now owns 221,992 shares of the company’s stock valued at $1,720,000 after purchasing an additional 9,438 shares during the last quarter. Paloma Partners Management Co bought a new stake in Endo International during the fourth quarter valued at approximately $122,000. Oakbrook Investments LLC bought a new stake in Endo International during the fourth quarter valued at approximately $133,000. LMR Partners LLP bought a new stake in Endo International during the third quarter valued at approximately $148,000. Finally, Xact Kapitalforvaltning AB bought a new stake in Endo International during the fourth quarter valued at approximately $157,000. Institutional investors and hedge funds own 96.54% of the company’s stock.
About Endo International
Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.
Receive News & Ratings for Endo International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International and related companies with MarketBeat.com's FREE daily email newsletter.